First data published using amplicon-based technology to detect ALK and ROS1 fusions
Highly sensitive detection of resistance mutations provides basis for optimising therapy for patients with relapsed NSCLC
Inivata announces that new clinical data from its collaboration with Dana-Farber Cancer Institute will be presented at the World Conference on Lung Cancer (WCLC).
The study involved a blind retrospective evaluation of Inivata’s InVision ctDNA liquid biopsy analysis to characterise and monitor the molecular profile of advanced non-small cell lung cancer (NSCLC) during genotype-directed therapy with osimertinib.
Inivata’s technology was shown to detect a full range of genotypes, including gene rearrangements, with an exquisite sensitivity and a high specificity. It was able to detect ALK and ROS1 fusions with high sensitivity, the first time this has been shown using amplicon sequencing. As published previously, there was excellent concordance with droplet digital PCR (ddPCR).
Commenting on the data, Geoffrey Oxnard, MD, thoracic oncologist and lung cancer researcher at Dana-Farber Cancer Institute, said, “These data show InVision is able to accurately deliver actionable information to clinicians about a range of genetic alterations and, in particular, its potential to inform the treatment of drug resistance. We look forward to further exploring this assay and its potential to impact patient outcomes.”
Clive Morris, Chief Medical Officer of Inivata, said, “This is the first time an amplicon based approach to next generation sequencing has been able to detect a full range of targetable genotypes in NSCLC, including ALK and ROS1 fusions. The study also provided further evidence of our platform’s exceptional sensitivity. The breadth of our panel and the sensitivity of InVision is a powerful combination and we continue to add to the body of evidence supporting its clinical utility.”
Read more here.